Rosen Law Firm Investigates TNDM Securities Fraud Claims After 19.9% Stock Drop
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Stock Price Drop: On August 7, 2025, Tandem Diabetes' stock plummeted by 19.9% following the announcement of a voluntary medical device correction for select t:slim X2 insulin pumps, indicating significant investor concerns regarding the company's transparency.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit on behalf of Tandem Diabetes shareholders to seek compensation for losses incurred due to misleading business information, with no out-of-pocket fees required from investors.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases.
- Investor Guidance: The firm advises investors to select qualified counsel with a proven track record in securities class actions to ensure optimal representation and avoid firms lacking relevant experience.
Analyst Views on TNDM
Wall Street analysts forecast TNDM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNDM is 26.33 USD with a low forecast of 14.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
8 Buy
10 Hold
0 Sell
Moderate Buy
Current: 20.490
Low
14.00
Averages
26.33
High
55.00
Current: 20.490
Low
14.00
Averages
26.33
High
55.00
About TNDM
Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
